Aiwu Ruth He
Georgetown University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aiwu Ruth He as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05063565 · TheraSphere With Durvalumab and Tremelimumab for HCCBoston Scientific Corporation · active not recruiting · Hepatocellular Carcinoma · principal investigator
- Ph2NCT00961571 · Sunitinib and Capecitabine for First Line Colon CancerGeorgetown University · terminated · Metastatic Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- gamma-OHPdG as a prognostic biomarker of HCC recurrence and its preventionU01CA220477 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2018 to 2022 · $441,284 awarded in 2022Same name and institution; not confirmed by an ID
- PROTOCOL_TITLEPILOT STUDY OF TANDEM MASS SPECTROMETRY IN PATIENTS WITH GI MALIM01RR023942 · NCRR · GEORGETOWN UNIVERSITY · fiscal years 2008 to 2009 · $11,222 awarded in 2009Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:53 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.Lancet Oncol · 2020476 citationsRCR 19.5
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol · 2024300 citationsRCR 38.0
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.Clin Cancer Res · 2018206 citationsRCR 6.0
- Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.J Clin Invest · 2021108 citationsRCR 5.3
- 94 citationsRCR 11.3
- A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.Cancer Chemother Pharmacol · 201886 citationsRCR 3.7
- Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.J Hepatol · 202581 citationsRCR 16.5
- 78 citationsRCR 2.0
- 67 citationsRCR 1.9
- 66 citationsRCR 3.2